PANG: Pangaea Oncology, S.A. - Summary | Jitta

Pangaea Oncology, S.A.

ESP:PANG

Price
€1.55
Loss Chance
54.2%
2.61JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
128 / 143
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (38)
Recent Business Performance (29)
Financial Strength (39)
Return to Shareholders (2)
Competitive Advantage (31)
Jitta Signs
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 95.58% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
2.61
100.00%
4.50
171.75%
COMPANY DESCRIPTION
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnostic platforms validation and pre-clinical services. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Zaragoza, Spain.